Another consideration for GLP-1/GIP/GCG agonists is their potential negative impact on lean mass [32]
Aggregation-induced emission: phenomenon, mechanism and applications
Spain: Market on fire According to data from consulting firm IQVIA shared with El Confidencial Digital outlet, the Spanish pharmaceutical market saw turnover for weight-loss medications exceed 484 million in 2024a 65% increase from 293 million in 2023
One big thing : If you have a chronic health condition that contributes to or creates joint pain, your first stop should be at your physicians office to seek an informed recommendation
Some patients experience less nausea with tirzepatide despite similar or greater weight loss, possibly due to GIPs modulating effects on gastric function
However, developing fit-for-purpose cell-based nAb assays present multiple challenges, especially when excessive drug level in patient samples interferes with nAb detection and decreases assay sensitivity [Citation3]